Formulation and in vitro evaluation of dermal delivery systems for psoriasis treatment

Psoriasis is a common, chronic inflammatory disease that affects 2-3% of the population. Treatment of psoriasis is needed to be suitable, be effective and last for long time for disease management. Psoriasis is a chronic and recurrent disease, it significantly affects the patients quality of life and leads to physico-social deficiency. In this study, our aim is to treat the disease and to avoid iteration. As it is a RAR receptor selective retinoid derivative and capable of downregulating gene expression tazaroten is selected for the formulations. Psoriatic skin is inflammated and skin structure is distrupted. Conventional treatments affects the psoriatic skin and frequently reported to cause, side effects like irritation resulting with discontinuing of the therapy. This study targeted to minimize the side effects of tazarotene and increase the patient compliance by providing long term drug release with solid lipid nanoparticles, solid lipid nanoparticle containing in situ gel and in situ gel formulations. Characterization studies of the formulations were completed and investigated. In vitro drug release studies of optimum formulations were evaluated. In addition, microbiological studies and biocompliability studies of the optimum formulation were performed and investigated. In conclusion, solid lipid nanoparticle, solid lipid in situ gel and in situ gel formulations are evaluated to overcome the side effects of tazaroten and increase the efficacy of therapy. Optimum formulations are found to be successfully able to increase patient compliance by providing extended drug release, decreasing the frequency of the dosage form.